Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Vericel Corporation

VCEL

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Last trade $57.88
Day change +$0.40 (+0.70%)
Day range $56.87 – $58.90
Volume 307,022
Market cap $2.93B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.93B
Price / earnings
88.06×
Price / book
7.64×
Price / sales
9.05×
EV / sales
8.64×
EV / EBITDA
69×

Profitability

Earnings per share
$0.65
Return on assets
6.44%
Return on equity
8.67%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.13×
Quick ratio
4.82×
Cash ratio
2.44×

Cash flow

Price / cash flow
44.91×
Price / free cash flow
50.67×
Free cash flow
$57.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VCEL, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$85.37M$77.46M$68.43M$92.92M$67.5M$63.24M$52.6M$75.38M
Cost of revenue$22.76M$21.06M$19.16M$19.79M$17.92M$16.63M$16.33M$16.88M
Gross profit$62.61M$56.4M$49.27M$73.13M$49.59M$46.61M$36.27M$58.5M
Selling, general and administrative$43.54M$48.48M$49.23M$43.46M$39.82M$41.91M$41.8M$35.1M
Research and development$6.89M$7.49M$8.1M$7.25M$6.32M$6.73M$7.26M$4.92M
Total operating expenses$50.42M$55.97M$57.33M$50.71M$46.14M$48.64M$49.07M$40.02M
Operating income$12.19M$434K-$8.06M$22.42M$3.45M-$2.03M-$12.79M$18.48M
Interest expense-$160K-$160K-$160K-$162K-$158K-$157K-$153K-$154K
Income before taxes$14.16M$2.21M-$6.3M$24.1M$5.07M-$553K-$11.25M$19.96M
Income taxes$0$0$0$859K$0$0$0$148K
Net income$14.16M$2.21M-$6.3M$23.24M$5.07M-$553K-$11.25M$19.81M
Net income attributable to common shareholders$14.16M$2.21M-$6.3M$23.24M$5.07M-$553K-$11.25M$19.81M
EBITDA$15.81M$4.05M-$4.8M$25.5M$6.39M$797K-$10.11M$19.96M
Basic earnings per share$0.28$0.04-$0.12$0.46$0.10-$0.01-$0.23$0.40
Diluted earnings per share$0.27$0.04-$0.12$0.41$0.10-$0.01-$0.23$0.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.

Zacks Investment Research

Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy?

Vericel Corporation (VCEL) has received a Zacks Rank #1 (Strong Buy) rating due to significant upward revisions in earnings estimates. The company's consensus estimates for the current quarter and full year have increased substantially, with current-quarter earnings expected at $0.62 per share (+37.8% YoY) and full-year earnings at $0.73 per share (+128.1% YoY). The stock has gained 43.8% over the past four weeks, reflecting investor confidence in its earnings growth prospects.

GlobeNewswire Inc.

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

Vericel Corporation reported strong Q2 2026 results with total revenue increasing 22% to $77.5 million and MACI revenue growing 23%. The company raised its full-year 2026 revenue guidance to $330-$340 million and announced a $200 million share repurchase program. Net income reached $2.2 million with free cash flow of $14.3 million, demonstrating sustained profitability and cash generation.

GlobeNewswire Inc.

Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight

The global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth engine with recent approvals of iPSC-based therapies in Japan.

GlobeNewswire Inc.

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Vericel Corporation announced preliminary 2025 financial results with total revenue of $276 million, driven by MACI revenue of $239.5 million. The company achieved 23% fourth quarter revenue growth, 74% gross margin, and 26% adjusted EBITDA margin, with GAAP net income profitability for the second consecutive year. The company completed its MACI sales force expansion and initiated a clinical study for MACI Ankle, while maintaining $200 million in cash with no debt.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 16, 20131-for-20reverse split